Cristina B Hofer1, Mauro Schechter, Lee H Harrison. 1. Infectious Diseases Service, Hospital Universitário Clementino Fraga Filho, Department of Preventive Medicine, Universidade Federal do Rio de Janeiro, Brazil. cbhst13br@yahoo.com
Abstract
OBJECTIVE: Brazil provides antiretroviral therapy (ART) to HIV-infected persons free of charge. The objective of this study was to investigate factors associated with ART failure in patients receiving free ART in public clinics in Brazil. METHODS: This is a cross-sectional study of adults taking ART for 6 to 24 months in 5 public clinics in Rio de Janeiro. Patients were interviewed and their charts were reviewed. The following definitions of response to therapy at 6 months were used: virologic responders (VR), > or =1 log reduction in plasma viral load (VL); immunologic responders (IR), increase of > or = 50 CD4 cells/mL; complete responders (CR), both VR and IR; and nonresponders (NR), neither VR nor IR. RESULTS: Of 211 patients enrolled, 173 (82%) were VR, IR, or CR and 38 (18%) were NR. Of the responders, 28 (13%) were IR, 32 (15%) were VR, and 113 (53%) were CR. In multivariate analysis, factors associated with NR were less than 80% adherence (OR = 8.6; 95% CI, 2.9-25.7), baseline CD4 count (OR = 0.5 per 50 cells/mL; 95% CI, 0.2-1.1), interval between starting ART and first VL/CD4 testing (OR = 1.4 for each month; 95% CI, 1.1-1.8), opportunistic disease after starting ART (OR = 6.8; 95% CI, 1.4-34.0), inability to read prescription (OR = 3.9; 95% CI, 1.4-10.9), not believing physician is knowledgeable about HIV (OR = 4.0; 95% CI, 1.1-15.0), not having a friend with HIV (OR = 6.1; 95% CI, 1.7-21.8), believing ART will make him/her ill (OR = 5.6; 95% CI, 1.7-18.8), and believing ART will delay HIV progression (OR = 0.001; 95% CI, 0.0-0.2). CONCLUSION: The proportion of patients responding to ART in Brazil was similar to reports from developed countries, suggesting that ART can be used successfully in developing countries. Variables related to adherence, knowledge, and perceptions about ART were associated with a lack of response to ART. These findings have important implications for developing nations that are considering increased access to ART.
OBJECTIVE: Brazil provides antiretroviral therapy (ART) to HIV-infectedpersons free of charge. The objective of this study was to investigate factors associated with ART failure in patients receiving free ART in public clinics in Brazil. METHODS: This is a cross-sectional study of adults taking ART for 6 to 24 months in 5 public clinics in Rio de Janeiro. Patients were interviewed and their charts were reviewed. The following definitions of response to therapy at 6 months were used: virologic responders (VR), > or =1 log reduction in plasma viral load (VL); immunologic responders (IR), increase of > or = 50 CD4 cells/mL; complete responders (CR), both VR and IR; and nonresponders (NR), neither VR nor IR. RESULTS: Of 211 patients enrolled, 173 (82%) were VR, IR, or CR and 38 (18%) were NR. Of the responders, 28 (13%) were IR, 32 (15%) were VR, and 113 (53%) were CR. In multivariate analysis, factors associated with NR were less than 80% adherence (OR = 8.6; 95% CI, 2.9-25.7), baseline CD4 count (OR = 0.5 per 50 cells/mL; 95% CI, 0.2-1.1), interval between starting ART and first VL/CD4 testing (OR = 1.4 for each month; 95% CI, 1.1-1.8), opportunistic disease after starting ART (OR = 6.8; 95% CI, 1.4-34.0), inability to read prescription (OR = 3.9; 95% CI, 1.4-10.9), not believing physician is knowledgeable about HIV (OR = 4.0; 95% CI, 1.1-15.0), not having a friend with HIV (OR = 6.1; 95% CI, 1.7-21.8), believing ART will make him/her ill (OR = 5.6; 95% CI, 1.7-18.8), and believing ART will delay HIV progression (OR = 0.001; 95% CI, 0.0-0.2). CONCLUSION: The proportion of patients responding to ART in Brazil was similar to reports from developed countries, suggesting that ART can be used successfully in developing countries. Variables related to adherence, knowledge, and perceptions about ART were associated with a lack of response to ART. These findings have important implications for developing nations that are considering increased access to ART.
Authors: Mison Dahab; Salome Charalambous; Alan S Karstaedt; Katherine L Fielding; Robin Hamilton; Lettie La Grange; Gavin J Churchyard; Alison D Grant Journal: BMC Public Health Date: 2010-07-22 Impact factor: 3.295
Authors: Suely H Tuboi; Mauro Schechter; Catherine C McGowan; Carina Cesar; Alejandro Krolewiecki; Pedro Cahn; Marcelo Wolff; Jean W Pape; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Daniel R Masys; Bryan E Shepherd Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.731
Authors: Edward J Mills; Jean B Nachega; David R Bangsberg; Sonal Singh; Beth Rachlis; Ping Wu; Kumanan Wilson; Iain Buchan; Christopher J Gill; Curtis Cooper Journal: PLoS Med Date: 2006-11 Impact factor: 11.069
Authors: Alexandre Grangeiro; Maria Mercedes Escuder; Alex Jones Flores Cassenote; Alex Jones Flores Cassanote; Rosa Alencar Souza; Artur O Kalichman; Valdiléa G Veloso; Valdiléa Veloso; Maria Letícia Rodrigues Ikeda; Nêmora Tregnago Barcellos; Carlos Brites; Unai Tupinanbás; Noaldo O Lucena; Carlos Lima da Silva; Heloisa Ramos Lacerda; Beatriz Grinsztejn; Euclides Ayres Castilho Journal: PLoS One Date: 2014-05-01 Impact factor: 3.240
Authors: Maria Nnambalirwa; Caroline Govathson; Denise Evans; Lynne McNamara; Mhairi Maskew; Peter Nyasulu Journal: Trans R Soc Trop Med Hyg Date: 2016-12-01 Impact factor: 2.184
Authors: Katherine L Fielding; Salome Charalambous; Amy L Stenson; Lindiwe F Pemba; Des J Martin; Robin Wood; Gavin J Churchyard; Alison D Grant Journal: BMC Infect Dis Date: 2008-07-16 Impact factor: 3.090